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ABSTRACT
Distinct epigenomic profiles of histone marks have
been associated with gene expression, but questions
regarding the causal relationship remain. Here we
investigated the activity of a broad collection of ge-
nomically targeted epigenetic regulators that could
write epigenetic marks associated with a repressed
chromatin state (G9A, SUV39H1, Kru¨ppel-associated
box (KRAB), DNMT3A as well as the first targetable
versions of Ezh2 and Friend of GATA-1 (FOG1)).
dCas9 fusions produced target gene repression over
a range of 0- to 10-fold that varied by locus and cell
type. dCpf1 fusions were unable to repress gene ex-
pression. The most persistent gene repression re-
quired the action of several effector domains; how-
ever, KRAB-dCas9 did not contribute to persistence
in contrast to previous reports. A ‘direct tethering’
strategy attaching the Ezh2 methyltransferase en-
zyme to dCas9, as well as a ‘recruitment’ strategy at-
taching the N-terminal 45 residues of FOG1 to dCas9
to recruit the endogenous nucleosome remodeling
and deacetylase complex, were both successful in
targeted deposition of H3K27me3. Surprisingly, how-
ever, repression was not correlated with deposition
of either H3K9me3 or H3K27me3. Our results sug-
gest that so-called repressive histone modifications
are not sufficient for gene repression. The easily pro-
grammable dCas9 toolkit allowed precise control of
epigenetic information and dissection of the relation-
ship between the epigenome and gene regulation.
INTRODUCTION
While genomic DNA holds the key to the genetic code,
epigenetics offers another layer of information that estab-
lishes cell fate during development, aging and disease as well
as in response to the environment. Epigenetics is a means
by which the transcriptome (and thus the proteome) of a
cell can be changed without alteration of the genetic con-
tent. Epigenetic regulation is thought to be accomplished
through epigenetic marks such as post-translational mod-
ifications of histones and DNA methylation, and also via
other mechanisms involving non-coding RNAs (1,2). Re-
gions of active gene expression and open chromatin carry
a signature of epigenetic marks that is distinct from re-
pressed and heterochromatic regions (2). For example, hi-
stone acetylation is always associated with active transcrip-
tion, while different histone methylation marks are asso-
ciated with active versus repressed chromatin. Specifically,
tri-methylation of lysine 4 on histone H3 (H3K4me3) is
associated with active transcription, while tri-methylation
of H3K9 (H3K9me3) and H3K27 (H3K27me3) are asso-
ciated with repressed chromatin regions. There has been a
significant effort to decipher the relationship between epi-
genetic marks, regulatory element activity and gene regu-
lation. Large consortia projects such as ENCODE and the
Roadmap Epigenomics Project have mapped epigenetic sig-
natures across the human genome in many different cell
types and tissues, which have then been correlated with gene
expression (3,4). These association-based studies have pro-
vided epigenomic landscapes of epigenetic marks present at
promoters and other regulatory elements, but cannot dis-
sect the dynamic relationships between the epigenome and
transcriptional control. While some evidence suggests that
silencing of gene expression precedes de novo DNA methy-
*To whom correspondence should be addressed. Tel: +1 530 754 9134; Fax: +1 530 754 9658; Email: djsegal@ucdavis.edu
†These authors contributed equally to the paper as first authors.
C© The Author(s) 2017. Published by Oxford University Press on behalf of Nucleic Acids Research.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact
journals.permissions@oup.com
9902 Nucleic Acids Research, 2017, Vol. 45, No. 17
lation (5), the causal relationship between the presence of a
histone mark and gene expression is still unclear.
Epigenome editing is an emerging tool to alter epigenetic
marks at defined genomic loci (6). Precise DNA targeting
was first accomplished with the design of programmable
proteins based on zinc fingers (ZFs) and Transcription
Activator-Like Effectors (TALEs) (7,8). However, the field
has been revolutionized by the discovery of the RNA-
guided DNA-targeting platform CRISPR/Cas9 (clustered,
regularly interspaced, short palindromic repeat/CRISPR-
associated protein 9) (9,10). The platform consists of the
Cas9 nuclease protein and a single guide RNA (sgRNA)
that allows the nuclease to bind a specific DNA sequence
through RNA–DNA base pairing. The most commonly
used Cas9, from Streptococcus pyogenes, is only limited by
the requirement of a 5′-NGG-3′ protospacer-adjacent mo-
tif (PAM) immediately adjacent to a 20-nt DNA target se-
quence (11,12). Two single amino acid mutations in Cas9
(D10A, H840A) abolish its nuclease activity, giving rise to
anRNA-guidedDNA-binding protein that lacks enzymatic
activity (dCas9) (10). dCas9 can be fused to heterologous ef-
fector domains to regulate transcription in a highly specific
manner (13–15).
There has been considerable recent focus on dCas9-
tethered epigenetic enzymes that alter DNAmethylation. In
particular, dCas9 fusions to DNMT3A/B or TET1/2 have
been shown to target the deposition of 5-methylcytosine (5-
mC) or the acquisition of 5-hydroxy-mC (5-hmC, consid-
ered to be the initial step in the removal of DNA methy-
lation), respectively (16–21). Fewer studies have explored
dCas9 fusions with enzymes affecting histone modifica-
tions. Gene activation has been explored using the hi-
stone acetyltransferase p300, histone demethylase LSD1
and a H3K4 methylase (22–24). Gene repression has
been attempted using dCas9-KRAB fusions (15,25). The
Kru¨ppel-associated box (KRAB) domain recruits endoge-
nous chromatin modifying complexes including the KAP1
co-repressor complex (26,27) and the nucleosome remod-
eling and deacetylase (NuRD) complex (28) and thus has
the potential to both tri-methylate histone H3 on lysine 9
and to deacetylate histones. Catalytic domains from several
other enzymes that catalyze H3K9me3 (such as G9A and
SUV39H1) have been linked to either ZF or TALE DNA-
binding domains, causing repression of theHER2 gene pro-
moter (29). Although H3K27me3 is associated with repres-
sion, Ezh2 (the catalytic subunit of the Polycomb repressive
complex 2 (PRC2) that causes deposition of H3K27me3)
has not yet been studied as a fusion to a programmable
DNA-binding domain. Importantly, in these previous stud-
ies, only changes in gene expression were used to assess the
efficacy of the targeted epigenetic regulators. Few studies
have monitored the changes in histone modification at the
target site bound by the epigenetic regulator. However, such
studies are essential to dissect the cause-and-effect relation-
ship between histone modifications and transcriptional reg-
ulation.
In this study, we investigated a broad set of epige-
netic enzymes (epigenetic writers) and epigenetic recruiters
(peptides or proteins recruiting chromatin modifying com-
plexes) designed for producing transcriptionally repressive
histone marks when fused to a common dCas9 platform.
In addition to well-studied writers of H3K9me3 (G9A,
SUV39H1) and theKRAB repressor domain (6,30), we also
created and used fusions to Ezh2 (a writer of H3K27me3)
and to the N-terminal 45 residues of Friend of GATA-
1 (FOG1), which has been associated with acquisition of
H3K27me3 and loss of histone acetylation, (31,32); these
domains have not been previously investigated as dCas9 fu-
sions. The effects of the marks introduced by these proteins
on gene expression were compared to the effects of DNA
methylation by dCas9-DNMT3A. We show that dCas9 fu-
sions to catalytic domains of EZH2, G9A and SUV39H1,
as well as dCas9 fused to the N terminus of FOG1, are suf-
ficient for some level of repression of three different pro-
moters in two different cell types, but that repression is not
always correlated with the expected histone modification.
We show that the dCas9-like targeting protein dCpf1 was
not able to substitute for dCas9 in these experiments. Fi-
nally, we show that combinations of targeted effectors can
produce persistent silencing.
MATERIALS AND METHODS
Construction of dCas9 expression plasmids
A variety of epigenetic effectors were fused to hu-
man codon-optimized and catalytically inactive ‘dead’
Cas9 (dCas9) in different conformations. The improved
pCDNA3-dCas9 expression plasmid was obtained by alter-
ing the original dCas9 plasmid (33) using Gibson cloning.
The improved pCDNA3-dCas9 contains two nuclear local-
ization signals, a 3× Flag epitope tag as well as [(GGS)5]
amino acid linkers at the N- and C-terminus of dCas9 with
flanking restriction sites KpnI and NheI, respectively. Im-
proved dCas9 protein sequence is shown in Supplemen-
tary Figure S1. Effector domains were amplified using 2×
Phusion Master Mix (New England Biolabs) according to
the manufacturer’s instructions. Polymerase chain reaction
(PCR) primers for cDNA amplification of individual ef-
fector domains were designed with cloning vector over-
hangs for Gibson cloning. All primers are listed in Sup-
plementary Table S1. cDNA for G9A[SET], SUV[SET]
and DNMT3A was kindly provided by the lab of Mari-
anne Rots (29,34). DNMT3L expression plasmid pCDNA-
DNMT3L was a kind gift from Dr Fred Chedin (35).
Mouse Ezh2[FL] cDNA was synthesized by Bio Basic Inc.
Ezh2[FL] was used as a template to amplify the shorter
Ezh2[SET] domain. Catalytic mutants Ezh2[SET-Y641A]-
dCas9 and Ezh2[SET-Y726F]-dCas9 were created by site-
directed mutagenesis using the QuikChange II XL Site-
Directed Mutagenesis kit (Stratagene). Primers used for
mutagenesis are listed in Supplementary Table S1. KRAB
domain was amplified from dCas9-KRAB (33) and FOG1
cDNA was amplified from HEK293FT cells. Total RNA
was isolated from HEK293FT using the RNeasy mini kit
(Qiagen) and cDNA was synthesized using random hex-
amer primers using the RevertAid cDNA synthesis kit
(ThermoScientific). UsingGibsonAssembly (NewEngland
Biolabs), amplified cDNAs were cloned into either KpnI or
NheI digested dCas9 vector for N-terminal or C-terminal
fusions to dCas9, respectively. Finally, the FOG1 epigenetic
effector construct was Gibson assembled (New England
Biolabs). Protein sequences of dCas9-fusions are supplied
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in Supplementary Figure S1. For array of two, three and
four FOG1 domains to the N-terminus of dCas9, FOG1
monomer coding sequences were amplified separately by
PCR introducing a GS linker between individual monomer
coding sequences and the KpnI and FseI restriction sites
at the beginning of first monomer and the end of the last
monomer for each array. In addition, a BsaI endonuclease
site was added to either end of the FOG1 monomers and
each fragment contains a distinct four-base overhang that
directs the assembly of multiple monomers. Amplification
primers are listed in Supplementary Table S1. Two, three or
four monomer coding sequences were mixed with pFusA
plasmid for Golden Gate Assembly cloning with BsaI and
T4 DNA ligase (New England Biolabs). DNA fragments of
arrays of two, three and four FOG1 domains were digested
withKpnI andFseI and ligated into theKpnI/FseI digested
dCas9 plasmid.
Cloning of expressing plasmid
The cloning vector was obtained from Addgene (36, Ad-
dgene plasmid # 41824) and was linearized using the AflII
restriction enzyme. A total of 19-bp gRNA target sequences
were selected within 500 bp of the relevant gene pro-
moter using the online tool CHOPCHOP (37). Each gRNA
sequence was selected and incorporated into two 60mer
oligonucleotides that contained cloning vector overhangs
for Gibson assembly. After annealing and extending the
oligonucleotides to 100-bp, the PCR purified (PCR pu-
rification kit; QIAGEN) dsDNA was Gibson assembled
into the AflII linearized plasmid. Oligomers used to create
target-specific vectors are listed in Supplementary Table S2.
Construction of dCpf1 expression plasmids and crRNA
The inactive Cpf1 was generated by mutating the catalytic
domainAsCpf1 (D908A; (38)). This amino acid change was
induced through adding mutations in the primers during
PCR amplification with pcDNA3.1-hAsCpf1 (Addgene,
plasmid #69982) as template. Primers are listed in Supple-
mentary Table S3. Two PCR fragments were inserted into
the FseI/NheI linearized pCDNA3-dCas9 backbone using
Gibson assembly thereby replacing dCas9 with dCpf1. Ef-
fector domains were then added using KpnI and/or NheI
digested plasmid to generate N- and/or C-terminal dCpf1
fusions following the same principle as dCas9 fusions. This
step uses the same cDNA amplification primers as de-
scribed for dCas9 fusions. crRNA was designed to tar-
get 23-bp adjacent to the 5′-NTTT-3′ PAM. crRNA tar-
get sequence is listed in Supplementary Table S3. For Cpf1
cleavage assays and dCpf1 chromatin immunoprecipitation
(ChIP) assays, we amplified theU6-crRNA cassette by PCR
(39). The U6-crRNA cassette was then co-transfected with
dCpf1 expressing plasmids as described below. To deter-
mine repression by dCpf1 fusion proteins we co-expressed
plasmids containing the U6-crRNA cassette with plasmids
expressing dCpf1 fusions (40).
Cell lines and transfection
The human colon cancer cell line HCT116 (ATCC #CCL-
247) was grown inMcCoy’s 5AMedium supplemented with
10% fetal bovine serum and 1% penicillin/streptomycin.
Cells were maintained at 37◦C and 5% CO2. HCT116 cells
were authenticated by the Bioreagent and Cell Culture
Core, USC Norris Comprehensive Cancer Center. Cells of
50–60% confluency were transfected using Lipofectamine
3000 (Life Technologies) following the manufacturer’s in-
structions. Transfections for RNA extraction were per-
formed in 12-well plates using 625 ng dCas9 expression vec-
tor, 500 ng of equimolar pooled expression vectors and 125
ng pBABE-puro. Transfections with dCpf1 were carried out
using the same protocol except that U6-crRNA express-
ing plasmids were co-transfected with dCpf1 expressing
plasmids as described elsewhere (39). For ChIP assays and
DNA-methylation analysis, cells were plated in 10-cm2 cul-
ture dishes and transfection scaled up accordingly. Trans-
fection medium was replaced 24 h post-transfection with
growth medium containing 3 g/ml puromycin to enrich
for transfected cells. Subsequently, puromycin-containing
media was exchanged every 24 h. To assay for persistent
repression, media was switched to standard growth media
four days after transfection.
RNA extraction and reverse-transcription quantitative PCR
(RT-qPCR)
Transfected cells were rinsed in 1×DPBS and RNA sta-
bilized by adding 500 g RNAlater (Ambion) and stored
at 4◦C for up to 1 week. Total RNA was extracted 3–
4 days after transfection using the RNeasy Mini kit (QI-
AGEN) and 500 ng RNA were reverse-transcribed us-
ing the SuperScript VILO MasterMix (Invitrogen) accord-
ing to the manufacturer’s instructions. Real-time PCR
was performed in triplicate with 2× iQ SYBR mix (Bio-
Rad) using the CFX384 Real-Time System C1000 Touch
Thermo Cycler (BioRad) and the included software was
used to extract raw Cq values. Gene expression analy-
sis was performed with GAPDH as a reference gene in
at least two biological replicates using intron-spanning
HER2 primers (HER2-F 5′-GGGAAACCTGGAACTC
ACCT-3′; HER2-R 5′-GACCTGCCTCACTTGGTTGT-
3′), EPCAM primers (EPCAM-F 5′-CTGGCCGTAAAC
TGCTTTGT-3′; EPCAM-R 5′- TCCCAAGTTTTGAG
CCATTC-3′),MYC primers (MYC-F 5′- AAACACAAAC
TTGAACAGCTAC-3′; MYC-R 5′-ATTTGAGGCAGT
TTACATTATGG-3′) and GAPDH primers (GAPDH-F
5′-AATCCCATCACCATCTTCCA-3′; GAPDH -R 5′-CT
CCATGGTGGTGAAGACG-3′). Relative target gene ex-
pression was calculated as the difference between the target
gene and the GAPDH reference gene (dCq = Cq[target]-
Cq[GAPDH]). Gene expression results are indicated as fold
change to a reference sample (usually dCas9 without any ef-
fector domain), using the ddCq method. We applied a one-
way ANOVA (ANalysis Of VAriance) with post-hoc Tukey
HSD (Honestly Significant Difference) test to determine
statistical significance for different dCas9 fusions.
Chromatin immunoprecipitation (ChIP)-qPCR
For ChIP assays of histone marks, transfected cells were
cross-linked 3–4 days post transfection by incubation with
1% formaldehyde solution for 10 min at room temperature
9904 Nucleic Acids Research, 2017, Vol. 45, No. 17
and the reaction was stopped by the addition of glycine to
a final concentration of 125 mM. Cross-linked cell pellets
were stored at −80◦C. Chromatin was extracted and ChIP
performed using StaphA cells (Sigma–Aldrich, St Louis,
MO, USA) to collect the immunoprecipitates as previously
described (33,41) Briefly, chromatin was sheared to an av-
erage fragment size of 500-bp using a Bioruptor 2000 (Di-
agenode). A total of 10 g chromatin were used per ChIP
assay. ChIP enrichment was performed by incubation with
3 g H3K9me3 antibody (Abcam ab8898), 3 g H3K9me2
antibody (MP 07–441), 2 g H3K27me3 antibody (MP
07–449), 2 g H3K27ac antibody (Active Motif #39133)
or 2 g normal rabbit IgG (Abcam ab46540) for 16 h at
4◦C. Immuno complexes were bound to StaphA cells for 15
min at room temperature. For dCpf1 and dCas9 ChIP as-
says, HCT116 cells were transfected in 10 cm culture dishes
as described above, but puromycin selection was omitted.
After cross-linking of chromatin, ChIP assays were per-
formed using 3 g Flag antibody (SIGMA M2 F1804) at
4◦C overnight. Immuno complexes were captured with 3
g rabbit anti mouse antibody for 1 h at 4◦C and were
bound to StaphA cells for 15 min at room temperature.
After washing and reversal of cross-links DNA was puri-
fied using the QIAquick PCR Purification Kit (Qiagen).
ChIP-DNA and diluted Input control were used for sub-
sequent qPCR reactions with 2× SYBR FAST master-
mix (KAPA Biosystems) according to the manufacturer’s
recommendations using the CFX384 Real-Time System
C1000 Touch Thermo Cycler (BioRad). ChIP enrichment
was calculated relative to input samples using the dCq
method (dCq = Cq[HER2-ChIP]-Cq[input]). HER2 ChIP
amplification primers are as follows: HER2-ChIP-F (5′-
TTGGAATGCAGTTGGAGGGG-3′) and HER2-ChIP-
R (5′-GGTTTCTCCGGTCCCAATGG-3′). We applied a
one-way ANOVA (ANalysis Of VAriance) with post-hoc
Tukey HSD (Honestly Significant Difference) test to deter-
mine statistical significance for different dCas9 fusions.
DNA-methylation analysis
Genomic DNA from transfected and untreated
cells was isolated using the Quick-gDNA MiniPrep
kit (ZYMO). Bisulfite conversion was performed
using the EZ DNA Methylation-Lightning Kit
(ZYMO) following the manufacturer’s instructions.
Bisulfite-Sequencing PCR primers (HER2-BSP-F 5′-
GGAGGGGGTAGAGTTATTAGTTTTT-3′ and HER2-
BSP-R 5′-AAATAACAACTCCCAACTTCACTTT-3′)
were designed using MethPrimer (42). Bisulfite converted
DNA was used for PCR amplification with GoTaq poly-
merase (Promega) and the 152-bp PCR product was
purified with the QIAquick PCR Purification Kit (Qiagen).
Amplicons were inserted into the pCR4-TOPO TA vector
using the TOPO-TA-cloning kit (ThermoFisher) and
transformed into NEB5 competent cells. Plasmid DNA
from individual recombinant clones was isolated and
subjected to Sanger sequencing using M13F primers at
the College of Biological Sciences UC DNA Sequencing
Facility. Methylation status of CpGs for each clone was
determined by sequence comparison.
Single-strand annealing (SSA) recombination reporter assay
For the pPGK-mCherry reporter plasmid, the Cpf1 nu-
clease binding site (crRNA binding region on HER2 pro-
moter) was inserted between XhoI/BamHI sites, which is
flanked with 200-bp direct repeats derived from mCherry
as single-strand annealing (SSA) arms (43). The open read-
ing frame of the mCherry gene was interrupted by the in-
sertion of the relevant binding region and a series of three
stop codons (Supplementary Figure S2A). Nucleases caus-
ing double strand breaks at the target site induce SSA repair,
which leads to expression of functional mCherry protein
that can readily be detected by its fluorescence (Supplemen-
tary Figure S2B). To evaluate cleavage activity, pcDNA3-
Cpf1 and pcDNA3-dCpf1, were co-transfected with the
three PCR amplified U6-crRNAs cassette and the mCherry
reporter plasmid in HEK293T cells. Cells were observed 48
h post-transfection.
Western blot analysis
Transfected cells were lysed 48 h post-transfection in
1×RIPA buffer (Millipore) supplemented with protease in-
hibitor cocktail (Roche). Protein concentrations were de-
termined by Bradford assay (BioRad) and 20 g pro-
tein were separated on a 4–15% TGXTM gel (BioRad) in
Tris/Glycine/Sodium dodecyl sulphate buffer and trans-
ferred onto nitrocellulose membranes. Protein loading was
evaluated by Ponceau S stain. After rinsing the mem-
brane with deionized water, non-specific antigen binding
was blocked in TBST buffer (50 mM Tris, 150 mM NaCl
and 0.1% Tween-20) with 5% nonfat dry milk (Cell Signal-
ing). Membranes were incubated with primary antibody in
blocking solution at 4◦C over night. We used monoclonal
antibodies against Flag (1:1000; SIGMA M2 F1804) or
anti beta-actin (1:2500; SIGMA A5441). Membranes were
washed with TBST three-times for 10 min before mem-
branes were incubated with horseradish peroxidase conju-
gated anti mouse secondary antibody at room temperature.
After 45 min, the membrane was washed three-times in
TBST and proteins were visualized with Amersham ECL
Prime Western Blotting Detection Reagent (GE Health-
care) and autoradiobiography film.
RESULTS
Systematic evaluation of repression by dCas9 fused to cat-
alytic domains of histone lysine methyltransferases G9A and
SUV39H1
Epigenetic effector domains for H3K9 methylation have
been previously fused to artificial ZF proteins (ZFP) to af-
fect transcriptional regulation in a targeted manner. More
specifically, the C-terminal end of ZFP E2C, which targets
the HER2 promoter, had been previously fused to the cat-
alytic SET (Su(var)3-9, Enhancer-of-zeste and Trithorax)
domains of the histone methyltransferases (HMT) G9A or
SUV39H1 (here referred to as G9A[SET] and SUV[SET],
respectively; Figure 1A), and was shown to repress endoge-
nousHER2 gene expression (29). In order to test the frame-
work for the repressive and epigenetic activity of RNA-
guided dCas9 fusions, we fused G9A[SET] and SUV[SET]
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Figure 1. N-terminal fusions of H3K9 methyltransferases to dCas9 repress HER2 gene expression independent of histone methylation. (A) Schematic
representation of the H3K9 histone methyltransferases (HMT) G9A and SUV39H1, with protein domains indicated. Regions that were fused to dCas9 are
labeled asG9A[SET] and SUV[SET]. (B) The genomic target sites of the three that target dCas9 to a 500-bp region of theHER2 promoter. ENCODE tracks
ofDNaseHS,H3K4me3 andH3K27A inHCT116 are shown. (C) The design of dCas9 fusion proteins. dCas9 fusions containedN-terminal andC-terminal
nuclear localization domains (NLSs), as well as anN-terminal 3XFLAGepitope tag. dCas9 fusion proteins contained the histonemethyltransferase effector
domain (ED) at the N-terminus, C-terminus or both the N- and C-termini (labeled [N], [C] and [N+C], respectively). A 15-aa linker [(GGS)5] separates the
dCas9 and the EDs. (D) Relative HER2 mRNA levels resulting from dCas9-ED fusions compared to dCas9 with no ED was determined by RT-qPCR in
HCT116 cells after co-transfection of plasmids expressing the indicated dCas9 fusions with the three sgRNAs targeted to theHER2 promoter (Tukey-test,P
< 0.01, n= 2 independent experiments each; mean± SEM). (E) H3K9me3 ChIP-qPCR enrichment at theHER2 promoter in HCT116 cells co-transfected
with three sgRNAs targeted to the HER2 promoter and the indicated N-terminal dCas9 fusions (Tukey test, *P < 0.05, n = 2 independent experiments;
mean± SD). The number above the bar indicates the fold-increase in H3K9me3 enrichment relative to dCas9 with no ED. ChIP assays using normal rabbit
IgG were used as negative controls. (F) ChIP-qPCR enrichment of K3K27me3 and H3K9me2 at theHER2 promoter in HCT116 cells co-transfected with
three sgRNAs and the indicated dCas9 fusions (No comparisons were significant, n = 2 independent experiments; mean ± SD).
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to dCas9 and used three single-guide (sg)RNAs simultane-
ously to target the dCas9 fusions to the promoter ofHER2
(Figure 1B and Supplementary Table S2). Effector domains
were fused to either the N-terminus, the C-terminus or both
the N- and C-termini of dCas9 to determine the most effec-
tive configuration for the dCas9-fusions (Figure 1C). Crys-
tal structures have revealed that neither the N-terminus
nor C-terminus of dCas9 is in immediate proximity to its
bound DNA (44). We therefore introduced a linker of 15
amino acids [(GGS)5] between dCas9 and the effector do-
main to improve the ability of the effector domain to con-
tact the DNA or histones. Surprisingly, we found that the
domains fused to the C-terminal end of dCas9 were un-
able to repress transcription, whereas both N-terminal fu-
sions of G9A[SET]-dCas9 and SUV[SET]-dCas9 displayed
3.3- and 2.7-fold downregulation ofHER2mRNA, respec-
tively (Tuckey HSD test, P < 0.01; Figure 1D). Western
blot analysis confirmed that N- and C-terminal dCas9-
fusions were expressed at similar levels (Supplementary Fig-
ure S3A) and that differences in repressive activity were due
to the configuration of the dCas9 fusions. Having effector
domains at both the N- and C-terminus did not increase
the repressive capacity. Specifically, the repressive capacity
of SUV[SET]-dCas9-SUV[SET] (2.2-fold) was comparable
to that of the single SUV[SET]-dCas9, while G9A[SET]-
dCas9-G9A[SET] showed no repressive activity, suggesting
that the C-terminal G9A[SET] attenuated the activity of the
N-terminal fusion. Negative controls using a dCas9 with
no effector domain but co-transfected with the three sgR-
NAs, or an mCherry reporter plasmid only, had no effect
on HER2 expression. Since N-terminal fusions of effector
domains to dCas9 were most effective, we focused on these
in subsequent experiments.
Repression by dCas9-SUV[SET] does not require tri-
methylation of H3K9 at HER2 gene promoter
To determine if repression by G9A[SET]-dCas9 and
SUV[SET]-dCas9 is associated with tri-methylation of
H3K9, we performed histone ChIP-qPCR assays to quan-
titatively measure H3K9me3 enrichment at the HER2 pro-
moter. ChIP enrichment was evaluated relative to dCas9
that did not contain an effector domain. G9A[SET]-dCas9
co-transfected with the three guide-RNAs produced a 13-
fold increase in H3K9 tri-methylation compared to dCas9
with no ED (Tuckey HSD test, P < 0.05; Figure 1E),
whereas SUV[SET]-dCas did not increase H3K9me3 lev-
els. This result was surprising given that G9A[SET]-dCas9
and SUV[SET]-dCas9 caused similar levels of HER2 re-
pression (3.3- and 2.7-fold, respectively, Figure 1D). There-
fore, although the SUV[SET] domain was sufficient to re-
press HER2 transcription it was not sufficient to medi-
ate H3K9me3 addition. Importantly, our data suggest that
an increase in H3K9me3 at the target promoter was not
required for SUV39H1-mediated repressive activity. Thus,
some other activity of the SUV[SET] domainmay have been
responsible for the repression, since dCas9 alone did not
cause repression. One possibility is that other repressive hi-
stone marks were deposited to cause the repression. This
latter possibility was investigated by examining alternative
histone marks that have been associated with repression.
Neither H3K27me3 nor H3K9me2 marks changed at the
HER2 promoter when targeted by SUV[SET]-dCas9 (for
which H3K9me3 was expected but not observed) (Figure
1F). The lack of deposition of expected or alternative re-
pressive histone marks further supported the conclusion
that repression by SUV[SET]-dCas9 did not require histone
methylation.
Full-length histone methyltransferase Ezh2 is required for
H3K27 methylation, but H3K27me3 is not correlated with
repressive activity
H3K9me3 and H3K27me3 mark distinct regions in the
genome (45); H3K9me3 is a mark typical of constitutive
heterochromatin, while H3K27me3 is usually enriched on
facultative heterochromatin (2,46). It is possible that an
enzyme associated with the formation of facultative hete-
rochromatin could be effective inmodifying promoter activ-
ity. However, enzymes mediating the repressive H3K27me3
mark have not yet been targeted to a specific genomic locus
by dCas9. We therefore created dCas9 N-terminal fusions
with the full-lengthmousemethyltransferase (Ezh2[FL]), as
well as a truncated form (Ezh2[SET]) containing the CXC
and SET domains (aa482–746) but lacking some of the N-
terminal domains (Figure 2A). Both Ezh2[FL]-dCas9 and
Ezh2[SET]-dCas9 produced repression of HER2 gene ex-
pression (1.6-fold [Tuckey HSD test, P < 0.05] and 2-fold
[TuckeyHSD test,P< 0.01], respectively; Figure 2B). How-
ever, only Ezh2[FL]-dCas9 was able to deposit H3K27me3
at theHER2 promoter, producing a 9-fold enrichment com-
pared to dCas9 with no effector domain (Tukey HSD test,
P < 0.01, Figure 2C). Therefore, similar to the case of
SUV[SET]-dCas9, our data suggest that Ezh2 residues in
addition to those in the CXC and SET domains may be
required for H3K27 tri-methylation activity. We further
tested if gene repression by Ezh2[SET]-dCas9 was asso-
ciated with other known repressive histone marks. There
was no increase in H3K9me2 or H3K9me3 that could ex-
plain the repression caused by Ezh2[SET]-dCas9 (for which
H3K27me3 was expected but not observed) (Figure 2D).
The lack of deposition of expected or alternative repressive
histone marks again supported the conclusion that repres-
sion by Ezh2[SET]-dCas9 does not require histone methy-
lation.
Taken together, our results support a hypothesis that
neither H3K9me3 nor H3K27me3 must precede or are
causative for repression. A possible non-epigenetic mech-
anism for repression was the simple steric interference of
endogenous regulatory components by the binding of the
dCas9-ED fusions. dCas9 alone did not cause repression by
this mechanism, as cells transfected with only an mCherry
expression plasmid displayed HER expression at a level
similar to a dCas9 with no ED (Figure 3C). However,
the repression displayed by the dCas9-ED fusions above
suggests that these dCas9 appendages might produce in-
terference. This non-catalytic mechanism was investigated
using catalytic mutants of the Ezh2[SET] domain. Cat-
alytic sites for the Ezh2 SET domain have been identi-
fied and defined by their ability to contact and methy-
late H3K27, including invariant residues involved in tar-
geting lysine or S-adenosyl methionine (30,47). We there-
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Figure 2. N-terminal fusions of Ezh2H3K27methyltransferases to dCas9 repressHER2 gene expression independent of histonemethylation. (A) Schematic
representation of the H3K27 methyltransferase Ezh2. Regions of each protein fused to dCas9 are labeled Ezh2[SET] and Ezh2[FL], and protein domains
are indicated. (B) Relative HER2 mRNA production in cells co-transfected with a pool of three sgRNAs targeted to the HER2 gene promoter and the
indicated dCas9 fusions. Expression data are shown in comparison to cells transfected by dCas9 with no ED (Tukey-test, *P < 0.05, **P < 0.01, n = 2
independent experiments; mean ± SEM). (C) H3K27me3 enrichment was assessed for the indicated dCas9 fusion proteins as in Figure 1 (Tukey test, P <
0.01, n = 2 independent experiments; mean ± SD). (D) ChIP-qPCR enrichment of H3K9me2 and H3K9me3 at the HER2 promoter in HCT116 cells, as
in Figure 1F. (E) Schematic representation of Ezh2[SET] catalytic mutants. (F) Relative HER2 mRNA production using the indicated Ezh2[SET]-dCas9
fusions. Expression data are shown in comparison to cells transfected by dCas9 with no ED (ns, not significant; n = 2 independent experiments; mean ±
SEM).
fore mutated tyrosine 641 to alanine (Y641A) and tyro-
sine 726 to a phenylalanine (Y726F), creating Ezh2[SET-
Y641A]-dCas9 and Ezh2[SET-Y726F]-dCas9, respectively
(Figure 2E). If repressive activity is truly uncoupled from
epigenetic writing activity, the mutant fusions should re-
press gene expression similarly to the catalytically active
Ezh2[SET]. Indeed both, Ezh2[SET-Y641A]-dCas9 and
Ezh2[SET-Y726F]-dCas9 repressedHER2 expression simi-
lar to the wild-type Ezh2[SET]-dCas9 fusion (Figure 2F).
These data strongly suggest that some or all of the re-
pression observed using these dCas9-ED fusions could be
due to non-catalytic mechanisms such as steric interference.
However, since dCas9-G9A[SET] and Ezh2[FL]-dCas9 did
clearly deposit their expected epigenetic mark, these latter
data also reinforce that neither H3K9me3 nor H3K27me3
must precede or are causative for repression.
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Figure 3. The novel transcriptional repressor FOG1[1–45]-dCas9-FOG1[1–45] tri-methylatesH3K27 at the target promoter. (A)Models for two approaches
of targeted H3K27methylation mediated by dCas9-fusion proteins. Top: fusion of dCas9 to the enzyme Ezh2 directly tri-methylates H3K27 at the genomic
target region. Bottom: fusion of dCas9 to subunits or interaction domains of endogenous co-repressor complexes, such as FOG1[1–45]-dCas9 that interacts
with the nucleosome remodeling and deacetylase (NuRD) complex, recruits the NuRD complex to the target sites causing HDAC1/2-mediated H3K27
deacetylation, as well as facilitation of H3K27 tri-methylation through recruitment of the PRC2 complex. (B) Schematic of dCas9-FOG1[1–45] fusion
proteins. Fusions to the N- and/or C-termini of dCas9 are labeled with [N] and/or [C], respectively. Arrays of two, three and four FOG1[1–45] repeats
are fused to dCas9. NLSs, 3XFlag epitope tag and the 15-aa linkers [(GGS)5] are indicated. (C) Relative HER2 mRNA was assessed in HCT116 cells co-
transfected with a pool of three sgRNAs targeted to the HER2 promoter and the indicated dCas9-FOG1[1–45] fusions. Repressive activity was measured
relative to Cas9 with no ED (Tukey-test, *P< 0.05, **P< 0.01, n= 2 independent experiments; mean± SEM). Negative control cells (‘−’) were transfected
with mCherry reporter plasmid instead of dCas9. (D) H3K27ac and H3K27me3 enrichments were assessed by ChIP-qPCR at the HER2 promoter after
transfection with a dCas9 with no ED or FOG1[1–45]-dCas9-FOG1[1–45] (Tukey test, ns, not significant; **P < 0.01; n = 2 independent experiments;
mean ± SD). ChIP assays using normal rabbit IgG were used as negative controls.
dCas9-FOG1[1-45] is a novel and efficient transcriptional re-
pressor producing H3K27 tri-methylation
As an alternative to the ‘direct tethering’ of the H3K27me3
methyltransferase Ezh2 (Figure 3A, top), we examined a
‘recruitment’ paradigm in which an endogenous modify-
ing complex could be recruited by a small peptide attached
to dCas9 (Figure 3A, bottom). Recruitment is also the
strategy used more frequently by natural transcription fac-
tors rather than the direct tethering of enzymes. One such
small peptide, the N-terminal 45 residues of Friend Of
GATA1 (FOG1), has been associated with tri-methylation
of H3K27. It has been shown that repression by the tran-
scription factors GATA1 and GATA2 is dependent on a
small conserved domain at the N-terminus of FOG1, which
in turn can bind directly to the NuRD complex (31). Re-
cruitment of the NuRD complex causes histone deacetyla-
tion at GATA1/2 target sites, followed by recruitment of
the PRC2 responsible for methylation of H3K27 (32) (Fig-
ure 3A, bottom). However, FOG1 had not previously been
used with any of the programmable DNA-binding plat-
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forms (ZFPs, TALEs or dCas9). FOG1[1–45] was fused to
the N-terminus, the C-terminus, or to both the N- and C-
termini of dCas9 (Figure 3B). In contrast to our results for
G9A[SET], SUV[SET] and Ezh2[SET], the FOG1[1–45]-
dCas9 fusion at the N-terminus did not give rise to a signifi-
cant decrease inHER2 transcription inHCT116 cells. How-
ever, the C-terminal dCas9-FOG1[1–45] repressed HER2
expression 3.2-fold (Tuckey HSD test, P = 0.004; Figure
3C). In further contrast, the strongest repression was ob-
served with dCas9 containing FOG1[1–45] fusions on both
the N- and the C-termini (6.2-fold; Tuckey HSD test, P =
0.001; Figure 3C). To evaluate possible synergistic activity
of multiple FOG1[1–45] effectors, we created N-terminal
dCas9-fusions with arrays of two, three or four FOG1[1–45]
repeats separated by 15-aa linkers [(GGS)5] (Supplemen-
tary Figure S1). However, these arrays failed to repress as
effectively as two FOG1[1–45] domains on either terminus,
perhaps due to their reduced expression levels compared to
the other FOG1-containing proteins (Supplementary Fig-
ure S3B).
Since FOG1[1–45]-dCas9-FOG1[1–45] (also referred to
as dCas9-FOG1 [N+C]) showed the strongest repression at
the HER2 target locus, we performed ChIP-qPCR assays
to determine enrichment of the histone marks H3K27ac
and H3K27me3. While the effect on H3K27ac was not sig-
nificant (Tukey test, P = 0.07), H3K27me3 was increased
5.8-fold (Tukey test, P < 0.01; Figure 3D). These data
demonstrate that targeting FOG1[1–45] to a specific site in
the genome is sufficient to cause H3K27 tri-methylation.
Taken together, these findings identify FOG1[1–45]-dCas9-
FOG1[1–45] as a novel transcriptional repressor that is as-
sociated with H3K27 tri-methylation.
A toolbox of targetable epigenetic regulators demonstrate
variable levels of repression at three loci in two cell types
The effect of targeted epigenetic reprograming might be
influenced by factors such as epigenetic marks, three-
dimensional interactions (e.g. between a promoter and an
enhancer, or localization of the DNA region to a sub-
nuclear compartment such as a transcriptional factory),
and initial expression levels, which may be locus and cell-
type dependent. We therefore investigated seven epige-
netic modifiers at the HER2, MYC and EPCAM promot-
ers in HCT116 and HEK293T cells. To be more compre-
hensive in our comparison of epigenetic modifiers hav-
ing a common dCas9 architecture, we additionally con-
structed KRAB-dCas9 and DNMT3A-dCas9. The KRAB
domain is a commonly used repression domain that like
FOG1 acts by recruitment of chromatin modifying com-
plexes. The KRAB domain achieves repression in asso-
ciation with recruitment of the KAP1 co-repressor com-
plex and is associated with H3K9me3 deposition (27). The
DNMT3A repression domain extends our toolbox to in-
clude targeted de novo DNA methylation (16–21). As re-
ported in previous studies (16,17,22,25,48), KRAB-dCas9
caused tri-methylation of H3K9 and DNMT3A-dCas9 in-
duced DNA methylation at the targeted HER2 promoter
(Supplementary Figure S4A and B, respectively). All dCas9
fusions caused some repression of HER2 expression in
HCT116 cells (Tuckey HSD test, P < 0.05 and P <
0.01; Figure 4A). Ezh2[SET]-dCas9, FOG1[1–45]-dCas9-
FOG1[1–45] and DNMT3A-dCas9 produced 2-fold down-
regulation of HER2 expression, placing them as somewhat
less efficacious than KRAB-dCas9, G9A[SET]-dCas9 and
SUV[SET]-dCas9. Differences in HER2 repression were
not correlated with differences in the amount dCas9-fusion
protein produced in cells (Supplementary Figure S3C).
HER2 is actively transcribed in HCT116 and HEK293T
cells and hence both contain features associated with active
promoters. Hallmarks of active promoters are aDNaseI hy-
persensitive site, acetylationmarks (H3K27ac andH3K9ac)
as well as methylation marks (H3K4me3 and H3K4me2)
(49). InHEK293T cells, only FOG1[1–45]-dCas9-FOG1[1–
45] and KRAB-dCas9 were able to downregulateHER2 ex-
pression bymore than 2-fold (2.1- and 2.4-fold, respectively,
Figure 4B). These data clearly demonstrate that although
both cell types have similar epigenetic profiles, epigenetic
dCas9-fusions can act in a cell-type dependent manner that
at the moment is not predictable.
We next tested dCas9 fusions at different gene pro-
moters. Very modest or no repressive activity was ob-
served at the MYC promoter in HCT116 cells (Tuckey
HSD test, P < 0.05 and P < 0.01; Figure 4C), while in
HEK293T cells KRAB-dCas9 caused robust downregula-
tion of MYC expression (6.2-fold) and DNMT3A-dCas9
and FOG1[1–45]-dCas9-FOG1[1–45] repressed MYC ex-
pression 3.7- and 2.3-fold, respectively (Tuckey HSD test,
P < 0.01; Figure 4D). No significant downregulation was
observed with G9A[SET]-dCas9, SUV[SET]-dCas9 and
Ezh2[SET]-dCas9. These latter effects may be due to the
increased copy number of the MYC gene in the HCT116
cell line. Finally, we targeted dCas9 fusions to the EPCAM
promoter in HCT116 cells (Figure 4E). Surprisingly, only
FOG1[1–45]-dCas9-FOG1[1–45] showed significant down-
regulation (2-fold, Tuckey HSD test, P < 0.05). Similar lo-
cus and cell-type differences in repression were observed for
different configurations of dCas9 with FOG1[1–45] (Sup-
plementary Figure S5). For each target, a pool between
three and six sgRNAs was used to target dCas9 fusions
to the gene promoter (Figure 4F). Taken together, these
data identify FOG1[1–45]-dCas9-FOG1[1–45] andKRAB-
dCas9 as the most potent transcriptional repressors at most
tested target sites. It is notable that direct fusions of dCas9
with chromatin modifying enzymes are much more suscep-
tible to differences in cell type or target region.
Effector fusions to the catalytically inactive Cpf1 (dCpf1) are
not active
To guide different epigenetic effector domains to unique
sites within the same or different regulatory elements, it
would be helpful to use orthogonal programmable DNA-
binding platforms. The RNA-guided endonuclease Cpf1,
a type V CRISPR/Cas system, offers a genome edit-
ing alternative to the type II CRISPR/Cas9 endonucle-
ase (39,50,51). Unlike Cas9, for which a CRISPR targeting
RNA and a trans-activating RNA are combined to form a
single gRNA, Cpf1 requires only a single CRISPR gRNA
(crRNA).Acidaminococcus (As)Cpf1 efficiently cleaves tar-
get DNA adjacent to a short T-rich PAM recognition site
(5′-TTTN-3′) whereas S. pyogenes (Sp)Cas9 requires a G-
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Figure 4. Variable repression mediated by ED-dCas9 epigenetic modifiers at three loci in two cell types. Relative mRNA production in HCT116 (A, C and
E) or HEK293T (B and D) cells co-transfected with a pool of sgRNAs targeted to the HER2 (A and B), MYC (C and D) or EPCAM (E) promoter with
the indicated dCas9 fusions. Expression data are shown in comparison to cells transfected by dCas9 with no ED (Tukey-test, *P < 0.05, **P < 0.01, (A
and E) n = 2 and (B–D) n = 3 independent experiments; mean ± SEM). (F) The positions of sgRNAs are indicated for each promoter.
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rich PAM site (5′-NGG-3′) hence broadening in principle
the number and diversity of target sites in the genome that
are accessible to precise gene editing. Since our goal is to de-
velop tools that target the epigenome, but do not cleave the
target DNA, we used a catalytically ‘dead’ Cpf1 [D908A]
(dCpf1; Figure 5A). To confirm loss of cleavage activity
of dCpf1, we performed SSA assays using a mCherry re-
porter system (52). The mCherry gene was split into two in-
active fragments containing overlapping homologies with a
HER2 promoter target site between them (Supplementary
Figure S2A). In cells, cleavage at the HER2 site will initi-
ate single strand annealing and generate an active mCherry
gene, causing cells to accumulate fluorescent mCherry pro-
tein. Co-transfection of wild-type AsCpf1 with a HER2 cr-
RNA resulted in red fluorescence; however, as expected, no
red fluorescence was observed when catalytically inactive
dCpf1 was used (Supplementary Figure S2B). We then con-
structed KRAB-dCpf1, EZH2[SET]-dCpf1, SUV[SET]-
dCpf1, DNMT3A-dCpf1, dCpf1-DNMT3A and FOG1[1–
45]-dCpf1-FOG1[1–45] (Figure 5A), and tested their re-
pressive activity at the HER2 promoter in HCT116 cells
using three crRNAs simultaneously (Figure 5B). Surpris-
ingly, none of the dCpf1 fusions were able to repress tran-
scription of HER2, while a dCas9 version of FOG1[1–45]-
dCas9-FOG1[1–45] demonstrated the expected repression
(Figure 5C). We then performed ChIP assays to confirm
that creating the catalytic mutant dCpf1 did not interfere
with the ability of dCpf1 to bind to its target site. dCas9
binding to the HER2 promoter was used as the gold stan-
dard and was targeted to the HER2 promoter either by
one sgRNA (sgRNA2) or a pool of three sgRNAs (Fig-
ure 1B). Similarly, dCpf1 was targeted to the HER2 pro-
moter with each individual crRNA or a pool of all three
crRNAs (Figure 5B). ChIP enrichments of dCas9 or dCpf1
were indistinguishable whether one or a pool of sgRNAs
or crRNAs was used (Tuckey HSD test, P = 0.001, Fig-
ure 5D). After this important preliminary finding, we next
assessed if addition of effector domains destabilizes dCpf1
binding to the target site. We assessed ChIP enrichment for
FOG1[1–45]-dCpf1-FOG1[1–45] andKRAB-dCpf1. Bind-
ing of FOG1[1–45]-dCpf1-FOG1[1–45] and KRAB-dCpf1
were not significantly different when compared to dCpf1
alone (TuckeyHSD test, Figure 5E). These data suggestma-
jor differences between the dCas9 and dCpf1 scaffolds and
mode of action when bound to the target site.
EZH2[FL]-dCas9 and DNMT3A-dCas9 establish persis-
tent repression, while FOG1[1-45]-dCas9-FOG1[1-45] and
KRAB-dCas9 drive robust transient repression
We next tested if transient expression of dCas9 fusion pro-
teins could cause persistent HER2 gene repression and
if combinations of dCas9 fusion proteins could increase
transient and/or persistent downregulation of HER2 ex-
pression. Transient repression was measured four days af-
ter transfection under puromycin selection to enrich for
transfected cells, while the persistent effect was deter-
mined after cells were grown for an additional 10 days
in puromycin free media (Figure 6A). This procedure en-
riched for transfected cells but avoided selection of stably
integrated epigenetic modifier expression plasmids, ensur-
ing that persistent repression would be due to altered epi-
genetic states (data not shown). Repressive activity was de-
termined for DNMT3A fused to the N- or C-terminus of
dCas9 (DNMT3A-dCas9 and dCas9-DNMT3A, respec-
tively). DNMT3A-dCas9 and dCas9-DNMT3A caused
only modest downregulation of 1.5- and 1.4-fold, respec-
tively; however, the repression was persistent over 10 days
(Figure 6B). In contrast, KRAB-dCas9 achieved a 5-fold
downregulation of HER2, but expression was completely
restored 10 days later. KRAB-dCas9 dominated tran-
sient repression, and addition of DNMT3A-dCas9, dCas9-
DNMT3A or overexpressed DNMT3L neither increased
repression nor persistence (Figure 6B). We then assessed
the contributions of the two H3K27me3 producing fusions,
FOG1[1–45]-dCas9-FOG1[1–45] and Ezh2[FL]-dCas9, on
the level and persistence of repression. FOG1[1–45]-dCas9-
FOG1[1–45] downregulated HER2 expression 2-fold, but
HER2 expression reverted to normal after 10 days (Fig-
ure 6C). Addition of DNMT3A-dCas9 and overexpres-
sion of DNMT3L improved the persistence of downregula-
tion; however, the same expression level and persistence was
achieved by DNMT3A-dCas9 alone. Ezh2[FL]-dCas9 was
also able to cause a level of HER2 downregulation similar
to DNMT3A-dCas9. The level and persistence of repres-
sion by Ezh2[FL]-dCas9 was further enhanced by addition
of DNMT3A-dCas9 and overexpressed DNMT3L (Tuckey
HSD test, P = 0.02; Figure 6C). Taken together, FOG1[1–
45]-dCas9-FOG1[1–45] and KRAB-dCas9 produce a tran-
sient but strong repression, while Ezh2[FL]-dCas9 and
DNMT3A-dCas9 drive persistent but more modest repres-
sion.
DISCUSSION
Precise control of transcription and epigenetics at a defined
genomic locus provides an ability to dissect links between
the two processes in a way not formerly possible. In this
study, we generated a set of epigenome editing tools to de-
posit epigenetic marks typically associated with a repressed
chromatin state, including DNA methylation and histone
methylation (both H3K9me3 and H3K27me3). Our epi-
genetic fusions of dCas9 with HMT complement recently
described epigenetic editing tools, which have been mostly
focused on DNA methylation and demethylation (16–21).
Our study made use of a common dCas9 architecture and
assayed a broad assortment of epigenetic effector domains
at three loci in two cell types. Direct enzyme tethering versus
co-repressor recruitment strategies were also examined.
The major finding of this study was that transcriptional
repression was independent of deposition of the expected
repressive chromatin mark. While dCas9 alone did not pro-
duce repression, evidence from Ezh2[SET]-dCas9 catalytic
mutants (Figure 2F) suggested that some amount of repres-
sion was due to a non-catalytic activity of the effector do-
mains. This activity could occur by a mechanism such as
steric hindrance of endogenous activation factors, or by an
interactionwith other components of repression complexes.
A similar observation was recently reported by Wysocka
et al., in which the methyltransferase catalytic activity of
MII3/4 proteins was dispensable for transcription, but the
proteins themselves were required due to their protein bind-
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Figure 5. dCpf1-epigenetic fusions do not repressHER2 gene expression. (A) Schematic of dCpf1-fusions with ED. Catalytically inactive AsCpf1 contains
nuclease-inactivating mutation D908A (dCpf1). (B) UCSC genome browser graphic showing HER2 target regions of sgRNAs containing the 5′-NGG-3′
PAMrequired by dCas9, and crRNA target sites flanked by the 5′-NTTT-3′ PAMrequired by dCpf1.HCT116ENCODE tracks forDNaseHypersensitivity
(DNase HS) and H3K27ac binding are shown. (C) Abundance ofHER2mRNA was measured after co-transfection of HCT116 cells with a pool of three
crRNAs with the indicated dCpf1-ED fusions. No significant repression was observed compared to a dCpf1 with no ED. Negative control cells (‘−’)
were transfected with mCherry reporter plasmid instead of dCpf1. As a positive control, repression was assessed after co-transfection of dCas9 with no
ED or FOG1[1–45]-dCas9-FOG1[1–45] and three sgRNAs (Tukey-test, P < 0.01, n = 2 independent experiments; mean ± SEM). (D) dCas9 and dCpf1
enrichments were assessed byChIP-qPCRat theHER2 promoter after transfectionwith a dCas9 or dCpf1with noEDand the indicated sgRNAor crRNA.
Statistical significance was analyzed by combining enrichments in the absence of a sgRNA or crRNA (n = 2) and compared to dCas9 with sgRNA2 and
sgRNA pool data (n = 2) and with combined dCpf1/crRNA data (n = 4) (Tukey test, P = 0.001). (E) dCpf1 enrichments were assayed after transfection
with the indicated dCpf1 with no ED or the indicated fusion, and the three crRNAs (ns, not significant; n = 2 independent experiments; mean ± SEM).
ChIP assays using normal rabbit IgG as negative controls are shown.
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Figure 6. Combinations of epigenetic modifiers can achieve long-term
gene repression. (A) Schematic of experimental design for transient
transfection assays with partial puromycin enrichment. (B) Relative
HER2 mRNA production in HCT116 cells co-transfected with a pool
of three sgRNAs targeted to the HER2 gene promoter and combina-
tions of N- or C-terminal DNMT3A-dCas9 fusions, KRAB-dCas9 and
DNMT3L. (C) Relative HER2 mRNA production using combinations
ofN-terminalDNMT3A-dCas9,KRAB-dCas9,DNMT3L, FOG1[1–45]-
dCas9-FOG1[1–45] and Ezh2[FL]-dCas9. Expression data are shown in
comparison to cells transfected by dCas9 with no ED. Statistical signif-
icance was analyzed for the transient effect by comparing dCas9 fusions
to dCas9 without an effector domain after 4 days, while significance of
persistent repression was calculated by comparing dCas9 fusions to dCas9
without ED after 14 days (Tukey-test, *P < 0.05, **P < 0.01, n = 2 inde-
pendent experiments; mean ± SEM).
ing interactions with other factors (53). However, several of
our tested domains were able to deposit their expected chro-
matin marks, but the chromatin marks appeared to produce
no additional gene repression (Figures 1E and 2C). These
data therefore demonstrate that deposition of so-called epi-
genetic repressive histone marks is not sufficient to cause
transcriptional repression.
The KRAB domain achieves repression in association
with recruitment of the KAP1 co-repressor complex which
contains the histone methyltransferase SETDB1, initiating
tri-methylation of H3K9 (27). The HMT SUV39H1 and
G9A have also been associated with H3K9me3. In contrast,
the two new functional domains introduced in this study,
Ezh2 and FOG1, are both associated with H3K27me3.
Ezh2 is a catalytic component of the PRC2 complex respon-
sible for H3K27me2/3. GATA-1 and its cofactor FOG1
bind to their genomic targets and repress gene expression
through recruitment of the NuRD complex. In biochemical
studies, FOG1[1–45] has been shown to interact with sev-
eral proteins that are part of the NuRD complex, such as
histone deacetylases HDAC1/2, CHD4, MBD2/3 as well
as MTA-1 and MTA-2 (31,54). NuRD-mediated deacety-
lation of H3K27 in turn allows for H3K27 tri-methylation
by the PRC2 complex (32,55). In our studies, FOG1[1–
45]-dCas9-FOG1[1–45] showed the strongest repression at
the HER2 target locus compared to any of the other ef-
fector domains tested, and also provided strong deposition
of H3K27me3. These findings present FOG1[1–45]-dCas9-
FOG1[1–45] as a newly described, highly efficient transcrip-
tional repressor associated with H3K27 tri-methylation.
The catalytic domains for Ezh2, G9A and SUV39H1
have been mapped to their C-terminal SET domains
(30,47). G9A[SET]-dCas9 was able to deposit H3K9me3
and a full-length Ezh2[FL]-dCas9 was able to deposit
H3K27me3, however SUV[SET]-dCas9 and Ezh2[SET]-
dCas9 were not able to deposit their expected marks. These
observations indicate that the SET domains of SUV and
Ezh2 are not sufficient for H3K9 or H3K27 tri-methylation
but that other parts of the full-length proteins may also
be required for histone methylation, at least in the context
of dCas9 fusion proteins. Perhaps this is not unexpected
as other domains of the Ezh2 protein are important for
interaction with members of the PRC2 complex, such as
Suz12 and EED, as well as other epigenetic modifying en-
zymes such as DNA methyltransferases (56,57). We also
note that SUV39H1 has Glu-repeat, Cys-repeat, Ankyrin
and Chomodomain domains upstream of the SET domain
(30), which may be important for catalytic (epigenetic writ-
ing) activity.
Two strategies can be used to epigenetically repress a spe-
cific endogenous gene: (i) direct targeting of a chromatin
modifying enzyme itself to DNA or (ii) recruitment of a
chromatin remodeling complex that contains several enzy-
matic capabilities. Although in nature, epigenetic enzymes
are rarely attached to DNA-binding domains directly, our
results using the enzymatic domains of EZH2, SUV and
G9A, as well as those of several other studies (16,17,22–
24), suggest that the first strategy can be effective experi-
mentally. Our novel transcriptional repressor consisting of
dCas9 fused to FOG1[1–45] is an example of the alternative
repression strategy based on recruitment of a co-repressor,
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as opposed to fusion of an enzymatic component to dCas9.
In addition to any functional advantages (e.g. improved
target-gene repression), the use of a short peptide is less
likely to interfere with endogenous regulatory factors at the
promoter than the direct tethering of large enzymes. It also
provides an opportunity to increase its effect by multiplex-
ing the short interaction peptides, such as is frequently done
with the herpes simplex VP16 activation domain to produce
the more effective VP64 (58,59). However, our data demon-
strate that some configurations of arrayed repeats can actu-
ally reduce protein expression, which could have accounted
for the reduced repression of our tandem FOG1 arrays. Fu-
ture designs of arrayed domains should consider such ef-
fects.
Our toolbox of epigenetic editors was found to have locus
and cell-type dependent effects on transcriptional repres-
sion, ranging from nearly no significant repression by any
factor at the MYC promoter in HCT116 cells to nearly 10-
fold repression by one factor at MYC in HEK293T cells.
HCT116 is a colon cancer cell line that contains amplified
regions in the genome resulting in additional copies of af-
fected genes. TheMYC gene is located in such an amplified
region in HCT116 cells and is thus present in three copies,
while there are two copies of the EPCAM andHER2 genes.
We cannot conclude whether the lack of repression is a cell-
type specific phenomenon per se or if it is more difficult
to achieve repression in the presence of additional MYC
gene copies. The effect of targeted epigenetic reprogram-
ing might also be influenced by existing epigenetic marks,
three-dimensional interactions and initial expression levels,
as well as other factors. Additional studies will be required
to understand the molecular basis for the observed locus
and cell-type dependent effects.
Surprisingly, none of the dCpf1-effector domain fusions
had an effect on gene expression, despite evidence of bind-
ing to the DNA target sites. In contrast to the G-rich PAM
site (5′-NGG-3′) required by the S. pyogenes (Sp)Cas9, Aci-
daminococcus sp. BV3L6 (As)Cpf1 is an RNA-guided nu-
clease that can use a short T-rich PAM recognition site (5′-
TTTN-3′) (39,50). Targeting both T-rich as well as C-rich
chromatin regions would broaden the number of target sites
in the genome that are accessible to epigenetic editing, and
would have been a useful orthogonal platform for targeting
different effectors to the same gene or simultaneously acti-
vating and repressing different genes in the same cell. No-
tably, there have not been any reports of dCpf1 based acti-
vators (e.g. VP64) or repressors (e.g. KRAB) in mammalian
cells. In Arabidopsis, fusions of catalytic inactive Cpf1 (As-
Cpf1[D908A] and LbCpf1 [D832A]) with three copies of
the SRDX repressor domain were used to repress a non-
coding RNA (60). Unfortunately, the dCpf1 used here was
not suitable for targeted transcriptional regulation. We also
note that Ezh2[SET]-dCas9 was observed to produce gene
repression through a non-catalytic process such as steric
hindrance (Figure 2F), but no such repression was observed
when Ezh2[SET] was tethered to dCpf1. These observations
suggest unexpected differences between dCas9 and dCpf1
platforms. However, it is possible that dCpf1 fusions will
be successful with different features or at different genomic
loci.
In addition to orthogonal gene regulation, epigenetic
editing holds the great potential for persistent changes in
gene expression without altering genetic sequence. In na-
ture, H3K9me3 and H3K27me3 are often associated with
silenced states of genes and other elements that are stable
over the lifetime of an individual. However, far less is known
about the transitions between active and silenced states. It
has been shown that targeting DNMT3A to a gene pro-
moter can be sufficient to achieve persistent gene silencing
(16,61,62). Although targeting DNMT3A results in methy-
lation at the target site, we and others have found the down-
regulation of gene expression is oftenmodest (17,48). In cer-
tain cell types, targeting KRAB and DNMT3L in addition
toDNMT3Awas required for persistent gene silencing (61).
However, KRAB-dCas9 had no effect on promoting persis-
tent silencing in our study, while the dCas9 fusion with the
epigenetic writer of H3K27me3 (Ezh2[FL]) facilitated per-
sistence.
Targeting epigenetic modifying enzymes allowed us to
interrogate the causal relationship between the epigenetic
marks and gene expression at the target site. Surprisingly,
we found that deposition of the expected histone modifica-
tion was not sufficient for transcriptional repression. This
result is similar to our previous finding that the level of
H3K27ac at an enhancer region is not correlated with the
activity of that enhancer in its endogenous genomic con-
text (63). Our current study has expanded the list of tools
available for epigenetic editing (6) to include new targeted
tools to deposit H3K27me3. However, almost all targeted
epigenetic modifiers reported to date have fallen well short
of producing the dramatic differences in the level of gene
repression observed in natural epigenetic states. Before we
can truly gain predictable epigenetic control of endogenous
gene expression, several features need to be better under-
stood: the length of the region requiring epigenetic modi-
fication, the persistence of the modified marks, the persis-
tence of machinery for reinforcing the marks, the effect of
multiple types of marks in a region and of course the re-
lationship between epigenetic marks and gene expression.
These issues will likely be the inspiration for many future
studies in the vibrant nascent field of epigenome editing.
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